XML 60 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Liquidity and Capital Resources (Details) - USD ($)
1 Months Ended 12 Months Ended
Jul. 29, 2019
Jun. 30, 2021
May 31, 2021
Aug. 31, 2020
Feb. 29, 2020
Dec. 31, 2021
Dec. 31, 2020
Jul. 31, 2020
Jul. 26, 2019
Liquidity [Abstract]                  
Cash and cash equivalents           $ 65,242,622 $ 28,839,565    
Term of common stock purchase agreement           30 months      
Percentage of shares of common stock that can be sold without shareholder approval 19.99%                
Share price (in dollars per share)                 $ 5.76
Issuance of common stock from equity transaction (in shares) 100,654                
Issuance of common stock from equity transaction $ 603,924                
Shares sold under common stock purchase agreement (in shares)           0      
Issuance of common stock (in shares)   6,088,235   6,900,000 10,000,000        
Sales price (in dollars per share)   $ 8.50   $ 2.75 $ 1.30        
Proceeds from issuance of shares   $ 51,700,000   $ 19,000,000.0 $ 13,000,000 $ 48,544,998 $ 29,756,502    
Proceeds from issuance of shares, net of underwriting discounts and commissions   $ 48,500,000   $ 17,100,000 $ 11,900,000        
Registered securities in Shelf Registration Statement available for future sale               $ 100,000,000  
Proceeds from sale of tax benefits     $ 4,500,000            
Shelf securities available for sale           $ 29,300,000      
Over-Allotment Option [Member]                  
Liquidity [Abstract]                  
Issuance of common stock (in shares)   794,117   900,000 769,230        
Minimum [Member]                  
Liquidity [Abstract]                  
Share price (in dollars per share)                 $ 0.50
Maximum [Member]                  
Liquidity [Abstract]                  
Shares of common stock to be purchased (in shares) 100,000                
Common stock to be purchased under common stock purchase agreement $ 20,000,000.0                
Shares of common stock that can be sold without shareholder approval (in shares) 1,034,979